Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Empagliflozin/Linagliptin/Metformin XR vs Trijardy XR in Healthy Subjects
NCT07213895Phase 1Completed
- Sponsor
- Humanis
- Start
- May 2025
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin, linagliptin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Humanis. Primary endpoints: Maximum concentration obtained at 72 hours, Area under the curve from time 0 to 72 hours and 1 more. Started May 2025; status: completed.
02
Drugs
empagliflozinlinagliptinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07213895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213895.